<DOC>
	<DOC>NCT01621633</DOC>
	<brief_summary>This is a study to characterize the pharmacokinetics as well as safety and tolerability of a single oral dose of LCZ696 200 mg in subjects with mild and moderate hepatic impairment compared to matched healthy subjects</brief_summary>
	<brief_title>A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>All subjects: Male and female subjects aged 1875 years. Body weight at least 55 kg with a body mass index between 1835 kg/m2. Hepatic impairment subjects: Mild or moderate hepatic impairment. All subjects: Clinical manifestations of postural symptomatic hypotension at screening or baseline. History of hypersensitivity to LCZ696 or to drugs of similar classes. Hepatic impairment subjects: Hepatic impairment due to nonliver disease. Treatment with any vasodilator, autonomic alpha blocker or beta2 agonist within 2 weeks of dosing. Encephalopathyy Stage III or IV. Primary biliary liver cirrhosis or biliary obstruction. History of gastrointestinal bleeding within 3 months prior to screening. Healthy subjects: Any surgical or medical condition which might significantly alter the distribution, or excretion of drugs, or which may jeopardize the subject in case of participation in the study. Use of prescription drugs, herbal supplements, and/or overthecounter medication, dietary supplements (vitamins included) within 2 weeks prior to initial dosing. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>hepatic impairment</keyword>
</DOC>